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Abstract.
Background: Mutant huntingtin (mHTT) is encoded by the Huntington’s disease (HD) gene and its accumulation in the
brain contributes to HD pathogenesis. Reducing mHTT levels through activation of the autophagosome-lysosomal pathway
may have therapeutic benefit. Transcription factor EB (TFEB) regulates lysosome biogenesis and autophagy.
Objective: To examine if increasing TFEB protein levels in HD mouse striatum induces autophagy and influences mHTT
levels.
Methods: We introduced cDNA encoding TFEB with an HA tag (TFEB-HA) under the control of neuron specific synapsin
1 promoter into the striatum of 3 month old HDQ175/Q7 mice using adeno-associated virus AAV2/9. The levels of exogenous
TFEB were analyzed using qPCR and Western blot. Proteins involved in autophagy, levels of huntingtin, and striatal-enriched
proteins were examined using biochemical and/or immunohistochemical methods.
Results: In HD mice expressing TFEB-HA, HA immunoreactivity distributed throughout the striatum in neuronal cell bodies
and processes and preferentially in neuronal nuclei and overlapped with a loss of DARPP32 immunoreactivity. TFEB-HA
mRNA and protein were detected in striatal lysates. There were increased levels of proteins involved with autophago-
some/lysosome activity including LAMP-2A, LC3II, and cathepsin D and reduced levels of mutant HTT and the striatal
enriched proteins DARPP32 and PDE10A. Compared to WT mice, HDQ175/Q7 mice had elevated levels of the ER stress
protein GRP78/BiP and with TFEB-HA expression, increased levels of the astrocyte marker GFAP and pro-caspase 3.
Conclusion:These results suggest that TFEB expression in the striatum of HDQ175/Q7 mice stimulates autophagy and lysosome
activity, and lowers mHTT, but may also increase a neuronal stress response.
Keywords: Adeno associated virus, autophagy, GRP78/BiP, huntingtin, Huntington’s disease, LC3, neurodegeneration,
striatum, TFEB
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INTRODUCTION
Huntington’s disease (HD) is caused by a mutation
in the gene encoding huntingtin (HTT) and results in
the formation of a mutant huntingtin (mHTT) that
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contains an expanded polyglutamine tract. One strat-
egy for therapy in HD is to reduce the levels of
mHTT in the brain. Two main pathways involved
in mHTT degradation are the autophagy and the
ubiquitin-proteasome systems. Autophagy mediates
the degradation of long-lived cytoplasmic proteins
by targeting them to lysosomes [1–6] and is thought
to be important for the clearance of disease pro-
teins. We showed that immunoreactive HTT in the
HD patient brain but not in control brain asso-
ciates with punctate structures in the cytoplasm that
by electron microscopy are multivesicular bodies,
organelles involved in protein degradation in
the autophagy/endosome/lysosomal pathways [7].
Autophagy has been implicated by us and others in
HTT clearance [6, 8–12] because proteins involved
in autophagy are activated or elevated by mHTT
overexpression and HTT fragments are degraded by
activators of autophagy. The lysosome is the final
pathway of clearance from autophagic degradation.
We showed in vitro that the presence of mHTT acti-
vates autophagy and increases levels of cathepsin D,
an endosomal/lysosomal enzyme, and cathepsin L, a
major protease of the lysosome [12].
Three main pathways of autophagy lead to
the lysosome: macroautophagy, microautophagy,
and chaperone-mediated autophagy [13]. Macroau-
tophagy is the major pathway and involves first the
formation of early autophagosomes that secondar-
ily fuse with lysosomes. Some of the key proteins
involved in macroautophagy include microtubule
associated light chain 3 (LC3, mammalian ATG8) and
Rab7. LC3 lipidates during early autophagosome for-
mation by conjugation to phosphatidylethanolamine
(LC3 I to LC3 II). This conjugation increases its
molecular mass, but accelerates its migration on SDS-
PAGE [14]. Increased levels of LC3 II were observed
in the brain of HD knock-in Q200 heterozygous mice
as early as 9 weeks of age [15]. Rab7 is involved in
later stages of macroautophagy, namely fusion of late
autophagosomes and endosomes with lysosomes [16,
17]. Chaperone mediated autophagy uses a specific
subset of cytosolic proteins with a motif recognized
by the heat-shock cognate chaperone 70 kDa protein
HSC70 [18, 19]. The chaperone-substrate complex
binds to a lysosomal membrane receptor, lysosome-
associated membrane protein 2A (LAMP-2A) [20]
and the chaperone mediated autophagy substrate pro-
teins translocate into the lumen of the lysosome where
they are degraded by hydrolases [21].
Transcription factor EB (TFEB) is a master
regulator of lysosome biogenesis and also drives
autophagosome formation [22]. TFEB can influence
the clearance of proteins involved in neurodegenera-
tion. In mouse models of Alzheimer’s disease, TFEB
expression activated lysosomal activity and reduced
neurofibrillary tangles and improved behavior and
synaptic neuronal measures [23]. TFEB expression
in astrocytes reduced amyloid beta load by targeting
the protein for degradation in lysosomes [24]. In a
cell model of Parkinson’s disease, TFEB expression
reduced the levels of alpha-synuclein aggregation
through activation of autophagy [25]. TFEB expres-
sion reduced levels of mHTT protein in a cell model
of Huntington’s disease [22] and Tsunemi et al. impli-
cated TFEB as an effector of PGC-1 activation in
clearing mHTT aggregates in N171-82Q HD mice
[26]. We hypothesized that exogenous expression
of TFEB itself could modulate levels of mHTT in
brain. We tested if direct overexpression of TFEB
in vivo could stimulate autophagy and reduce levels
of mHTT protein in the striatum of the HDQ175/Q7
mouse. We used viral delivery with adeno-associated
virus AAV2/9 to introduce HA tagged TFEB into the
striatum. To study the safety of TFEB-HA expres-
sion we measured the levels of striatal enriched
proteins DARPP32 [27] and PDE10A [28], exam-
ined astrocyte activation using glial fibrillary acidic
protein (GFAP), apoptosis activation using caspase
3 and PARP-1 and the ER stress response using
GRP78/BiP.
MATERIALS AND METHODS
Preparation of TFEB constructs and AAV vectors
Mouse TFEB coding sequence with C-terminal
HA-tag was subcloned from pAAV2.1-CMV-
TcFEB-HA plasmid [29] into the AAV backbone
with neuronally restricted (human synapsin 1, hSyn1)
promoter. Control vector was based on the same back-
bone and contained GFP under control of the hSyn1
promoter. Packaging of the plasmids into AAV2/9
was performed by the virus core facility at the Uni-
versity of Massachusetts Medical School.
Animals, surgery and stereotactic injections
An animal protocol A978-12 was approved by
the University of Massachusetts Medical School and
an animal protocol #2004N000248 was approved
by MGH SRAC. Heterozygous knock-in HDQ175/Q7
mice and WT littermates were obtained from Jackson
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Laboratories. Mice were deeply anesthetized using
Avertin (1.2% solution, 250 mg/kg). Viral injections
into the striatum were unilateral or bilateral and were
done by stereotaxic placement of a 10L NanoFil
microsyringe with a 33G beveled needle under control
of an UltraMicroPump (UMP3) microinjector with
SYS-Micro4 Controller (all WPI Inc.). Each injection
was 2l in volume and was delivered to the striatum
over a period of 8 minutes. The concentration was
6.8E+12genomecopies/mLforpAAV-TFEB-HAand
4.2E+12 for pAAV-hSyn1-GFP. A dose response was
not performed in advance of the experiments reported
here using hSyn1 promoter. The volume and concen-
tration of vector were known from a recent study of
NUB1 expression driven by hSyn1 promoter to maxi-
mize viral distribution to mouse striatal neurons with-
out toxicity [30]. The post injection survival period
was four or eight weeks. We noticed that the cage
behavior of TFEB-HA injected HDQ175/Q7 mice was
altered beginning 6 weeks after injection. No formal
behavioral testing was performed, but recordings of
mouse behavior during routine handling are provided
as Supplementary Video 1–3. Clasping (Supplemen-
tary Video 1), hyperactivity and some momentary
freezing(SupplementaryVideo2),which ischaracter-
isticof seizures, appeared inall theTFEB-HAinjected
HDQ175/Q7 mice. Such behaviors were not seen in
the non-injected mice (Supplementary Video 3) or
mice treated with AAV hSyn1 GFP at any time. One
HDQ175/Q7 mouse died 3 days prior to the scheduled
terminationof theexperiment.At theappropriatepost-
injection interval, mice were deeply anesthetized with
500 mg/kg Avertin and the brains were removed for
qPCR and biochemical assay or a cardiac perfusion
was performed with Phosphate Buffered Saline (PBS)
followed by 4% paraformaldehyde for immunohisto-
chemistry and immunofluorescence. A total of 4 WT
and 26 HDQ175/Q7 mice were used for the study. Sup-
plementary Table 1 lists the genotype of the mice,
gender, viral vector, and type of injection (bilateral,
unilateral).
Tissue preparation
Striatal tissue was dissected and small pieces from
the injection area in dorsal striatum were used for
RNA isolation. Remaining striatal tissue was pro-
cessed into crude homogenate (CH) and subcellular
fractions were obtained by low (P1, low speed pel-
let, 4000 g) and high speed centrifugation (high speed
supernatant S2 and high speed pellet P2, 100 000 g)
as described in our publications [8, 9, 31].
Relative quantiﬁcation of TFEB mRNA
expression by qPCR
Total RNA was extracted from striatal tissue using
Trizol (Ambion #15596-026) and further purified
using an RNeasy kit (Qiagen #74104). One micro-
gram of RNA was converted to cDNA using an
iScript cDNA synthesis kit (Bio-Rad #170-8890) per
manufacturer’s instructions (5 min. 25◦C, 30 min.
42◦C, 5 min. 85◦C, 20L reaction volume). cDNA
equivalent to 20 ng of input RNA was used per
reaction for quantitative real-time PCR (qPCR).
qPCR was performed in technical triplicates in
total reaction volume of 20L including 500
nM specific primers and 10L iQ SYBR Green
Supermix (Bio-Rad #170-8880) using an iCycler
iQ Multicolor Real-Time PCR Detection System
(Bio-Rad). Primers were: TFEB forward 5’-GACTC-
AGAAGCGAGAGCTAACA-3’, TFEB reverse 5’-
TGTGATTGTCTTTCTTCTGCCG-3, -actin
forward 5’-AGGTATCCTGACCCTGAAG-3’, -
actin reverse 5’-GCTCATTGTAGAAGGTGTGG-3’
[32], GAPDH forward 5’-AACAGCAACTCCCAT-
TCTTC-3’ and GAPDH reverse 5’-TGGTCCAGG-
GTTTCTTACTC-3’ [33]. Cycling parameters were:
10 min. 95◦C, 39x: 10 sec. 95◦C, 1 min. 60◦C
(including the data collection step). Threshold cycles
(Ct) were determined by Bio-Rad iCycler Software.
Levels of gene expression were quantified relative
to the mean expression of two housekeeping genes:
-actin and GAPDH. Technical replicates were
averaged and Ct values for each mouse were
calculated as Ct TFEB - average Ct reference (the
average Ct of two housekeeping genes). Two-tailed
unpaired Student’s t-tests on Ct values was used
to calculate differences in relative TFEB expression
levels between injection groups (N = 4 per group).
Relative expression levels for each animal were
calculated as Ct TFEB – average Ct TFEB of
control group (non-injected) and plotted as 2−Ct
(fold-change).
Biochemical studies
For the analysis of basal levels of HTT and
levels of autophagy/lysosomal markers in striatum
of HDQ175/Q7 mice by SDS-PAGE, protein sam-
ples were resolved on 12% Bis-Tris gels, 4–12%
Bis-Tris gels or 3–8% Tris-Acetate gels (NuPage,
Invitrogen), and transferred onto PVDF (for detect-
ing LC3) or nitrocellulose membrane (for all other
proteins). Methods for SDS-PAGE and Western blot
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(WB) for detecting HTT and autophagy related
proteins have been reported in our previous pub-
lications [31]. Western blots were probed with
antisera detecting HA epitope (Cell Signaling #2367,
1:1000), GFP (Cell Signaling #2956, 1:3000), HTT
(Ab1, [34], 1:3000 and Abcam EPR5526, 1:3000),
LC3 (Novus NB600-1384, 1:1000), LAMP-2A
(Invitrogen #512200, 1:4000), Rab7 (Cell Signal-
ing #9367, 1:1000), HSC70 (Enzo ADI-SPA-816,
1:1000), Cathepsin D (Millipore – Calbiochem
IM16, 1:40), DARPP32 (Abcam, EP720Y, 1:3000),
PDE10A (Abcam, EPR12835, 1:3000), GFAP (Mil-
lipore, Ab5804, 1:6000), Caspase-3 (Cell Signaling
#9665, 1:1000), PARP-1 (Cell Signaling #9532,
1:1000), GRP78/BiP (StressGen SPA-827, 1:1000),
and GAPDH (Millipore MAB374, 1:6000). All sig-
nals were detected using appropriate horseradish
peroxidase conjugated secondary antibodies (Jack-
son ImmunoResearch) and SuperSignal West Pico
Chemiluminescent Substrate. Images were obtained
using a CCD imaging system, quantified by densito-
metry in FiJi/ImageJ distribution and the results were
subjected to statistical analysis.
Immunohistochemistry
Brains from animals perfused with 4% para-
formaldehyde were post-fixed in 4% paraformalde-
hyde for 4 hours and stored in PBS (all at 4◦C)
until use. Serial sections (50m) were obtained using
a vibratome. Sections were blocked in 5% Normal
Donkey Serum in PBS with 1% bovine serum albu-
min (BSA) and 0.2% Triton X-100 for one hour at
room temperature. Primary antibodies were diluted
in the blocking solution and alternate series of sec-
tions from the same brain were incubated for 48
hours at 4◦C. The following primary antibodies were
used: antisera detecting HA epitope (Santa Cruz SC-
805, 1:100), GFP (Cell Signaling #2956, 1:400),
DARPP32 (Abcam EP720Y, 1:50000), and GFAP
(Millipore, Ab5804, 1:1500). After washing with
0.05% Tween-20 in PBS (PBST), sections were incu-
bated in biotinylated anti-rabbit antibody (Vector,
BA-1000,1:500)overnightat4◦C.Afterwashingwith
PBST, immunoperoxidase/diaminobenzidine (DAB)
detection was performed using Vectastain ABC Kit
Elite (Vector PK-6100) and a Metal Enhanced DAB
Substrate Kit (ThermoFisher 34065) according to
manufacturer’s protocol. Sections were placed on
gelatinizedslides,dried,dehydratedusingethanoland
xylene and mounted using Cytoseal 60 permanent
mounting medium (Richard-Allan Scientific 8310).
Immunofluorescence double labeling for HA and
NeuN was performed on some sections. The staining
procedure was as described for immunohistochem-
istry, with the following modifications: Sections were
incubated in a mix of primary antibodies (HA, Santa
Cruz SC-805, 1:100; NeuN Millipore, 1:100), fol-
lowed by thorough washing in PBST and incubation
in a mix of fluorescent secondary antibodies (anti-
rabbit Cy3 1:500 and anti-mouse bodipy 1:500,
both from Jackson ImmunoResearch). Nuclei were
counterstained with 4’,6-diamidino-2-phenylindole
(DAPI).
Images of immunoperoxidase labeled sections
were acquired using a Zeiss Axioskop microscope
with a Spot RT3 camera. Fluorescence stained sec-
tions were imaged using a Nikon Eclipse inverted
microscope with Bio-Rad Radiance 2000 confocal
laser scanning system.
Determination of staining intensity for DARPP32
Brightfield images of selected immunoperoxi-
dase/DAB labeled sections (3-4 sections per animal)
were obtained using a 2.5x lens to image the entire
striatum. Images were converted to grayscale and
inverted so that higher staining intensities were pre-
sented by higher numeric values. Using FiJi/ImageJ,
integrated intensity was measured in a square region
of interest (250 × 250m) in the striatal area where
TFEB-HA or GFP was distributed and in an area
of the striatum without distribution of TFEB-HA or
GFP. Values were expressed as a ratio and are reported
as percent reduction in DARPP32 staining intensity
in areas of HA or GFP immunoreactivity.
DARPP32 positive cell counting
Analysis of total number of DARPP32 positive
cells in the striatum of injected and control mice was
performed using the optical dissector/fractionator
probe in StereoInvestigator Software (Micro Bright-
field) and a Nikon Eclipse inverted microscope. Every
fourth coronal section through the region covering
the entire striatum was included in the counting pro-
cedure. A coefficient of error of < 0.1 was accepted
(CE Gundersen, m = 1).
Data analysis and statistics
Two-tailed unpaired Student’s t-test was per-
formed to compare control and TFEB-HA injected
groups. Kendal tau correlation coefficient was used
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to compare relative TFEB expression on mRNA and
protein levels in individual animals. Statistical signif-
icance was accepted if p < 0.05.
RESULTS
We selected the neuronal specific hSyn1 pro-
moter to drive TFEB-HA expression. HDQ175/Q7
mice were injected at age 3 months with AAV hSyn1
TFEB-HA or AAV hSyn1 GFP and evaluated at
two months post-injection together with age-matched
non-injected mice. An HA tag was used because
we found that 3 separate commercially available
antibodies directed against TFEB were not useful
for immunohistochemistry or Western blot. All HD
mice injected with AAV hSyn1 TFEB-HA showed
widespread distribution of immunoreactive HA in
the dorsal striatum of the injected side (Fig. 1A).
HA labeling appeared in cell bodies and processes
and localized to the nucleus (Fig. 1A, image 1).
Co-localization of HA with NeuN confirmed that
the TFEB-HA expression was present in neurons
(Supplementary Figure 1). No detectable HA label-
ing was observed in non-injected mice (Fig. 1B).
In the hSyn1 GFP injected mice, GFP immunore-
activity in the striatum was also widespread and
uniform (Fig. 1C). Analysis of adjacent sections
showed that immunoreactivity for DARPP32, which
is enriched in striatal neurons, was reduced in some
cell bodies and in neuropil in the areas overlapping
with HA labeling compared to areas without HA
Fig. 1. Immunohistochemistry for TFEB-HA, DARPP32 and GFAP in mice injected with AAV hSyn1 TFEB-HA, AAV hSyn1 GFP or
non-injected and examined 2 months post-injection: Immunoperoxidase labeling for HA (TFEB-HA) (A, B) or GFP (C) within the injected
or control striatum. Images from corresponding sections stained with DARPP32 (D, E, F) and GFAP (G, H, I) show extent of labeling within
the striatum. Numbered boxes correspond to areas displayed in the enlargements to the right. DARPP32 staining of cell bodies and processes
is diminished in the TFEB-HA affected area of striatum (D). Note increased GFAP labeling in the area of striatum affected by TFEB-HA
injection (G). N = 2 mice per treatment group.
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Fig. 2. TFEB mRNA quantification by qPCR and comparison to TFEB-HA protein levels. A) Relative quantification of TFEB mRNA in
non-injected and AAV hSyn1 TFEB-HA injected HDQ175/Q7 mice. Data are presented as a fold-change over mean of control group (non-
injected). Each point represents individual mouse and boxplots show overall data distribution (N = 4 mice per group). P-value from unpaired
t-test. B) Comparison of TFEB mRNA levels in individual animals to TFEB-HA protein levels detected by HA antibody. Bar graphs show
relative fold-change over mean of control group for mRNA and HA densitometry signal in crude homogenate normalized to GAPDH for
protein. Kendall tau correlation coefficient and corresponding p-value for mRNA/ crude homogenate protein level is provided. C) Western
blot for TFEB-HA protein levels as detected by HA antibody in P1 nuclear enriched fraction.
labeling (Fig. 1D, compare images 1 and 2 with 7
and 8). No difference in DARPP32 immunoreactiv-
ity was observed between the striata of non-injected
and hSyn1 GFP injected mice (Fig. 1E, F com-
pare images 9, 10 with 11, 12). Determination of
DARPP32 staining intensity and neuron counts (Sup-
plementary Table 2) showed decreased intensity in
AAV hSyn1 TFEB-HA injected mice compared to
non-injected and AAV hSyn1 GFP injected mice
and a reduced number of neurons (566,766.81 per
striatum for TFEB-HA vs 614,247.44 in GFP and
652,665.06 in non-injected mouse). These results
suggest that the reduction in DARPP32 immunoreac-
tivity is in part due to neuronal loss. In contrast to the
loss of immunoreactive DARPP32, GFAP immunore-
activity was strongly increased in striatal areas that
overlapped with HA distribution (Fig. 1G, compare
images 1 and 2 with 13), and also in adjacent cortex
and striatum (Fig. 1G, 14). GFAP immunoreactivity
was low in non-injected mice (Fig. 1H) and elevated
mainly near the needle track in AAV hSyn1 GFP
injected mice (Fig. 1I, compare images 5, 6 with 17,
18). Some HD mice were also injected with AAV
hSyn1 TFEB-HA (N = 2) or AAV hSyn1 GFP (N = 2)
and evaluated one month post-injection. The label-
ing for HA, DARRP32, GFAP, or GFP in the injected
striatum was similar to that of HD mice examined
at two months post-injection (data not shown). As
there was little difference in DARPP32 and GFAP
immunoreactivity between non-injected and AAV
hSyn1 GFP injected HDQ175/Q7 mice, we used non-
injected mice as the control group for the biochemical
experiments described below.
Quantiﬁcation of TFEB-HA transcript and
correlation with protein levels in striatum
of HDQ175/Q7 mice
We evaluated TFEB mRNA levels in AAV hSyn1
TFEB-HA injected mice at 2 months post-injection
by qPCR. Primers were specific for both endogenous
TFEB and TFEB-HA sequence. The average level
of TFEB mRNA was 23-fold higher in HDQ175/Q7
mice injected with AAV hSyn1 TFEB-HA com-
pared to endogenous TFEB message in mice that
were not-injected (Fig. 2A, p = 0.005). The range of
TFEB mRNA signal in individual injected mice was
from 60-fold to 5-fold (compared to the mean of the
non-injected group). The values for mRNA signal
significantly correlated with those for HA protein lev-
els measured by Western blot in corresponding crude
homogenates from the same mice (Fig. 2B, Kendall
τ = 1, p = 0.042). HA expression was also con-
firmed in the nuclear enriched P1 fraction (Fig. 2C),
indicating presence of exogenous protein in the
nucleus.
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Fig. 3. Activation of autophagy and reduction of mHTT in TFEB-HA treated striatum. A) Western blot analysis for LAMP-2A, LC3II,
and procathepsin D (proCTSD) in crude homogenates (CH) of HDQ175/Q7 mice injected with AAV hSyn1 TFEB-HA or non-injected. B)
Quantitative results of crude homogenate Western blots in A and Western blots in subcellular fractions (P1, S2 and P2). HSC70 and Rab7
in S2 fractions are included in the bar graphs along with the results for LAMP-2A. C) Western blots of HTT levels in crude homogenate
(CH) and in membrane fractions P1 and P2 detected with anti-HTT aa1-100 antibody EPR5526. D) Bar-graphs represent the results of
densitometry for mHTT and WT HTT on Western blots shown in C. Mutant HTT levels in the AAV hSyn1 TFEB-HA injected mice are
reduced compared to the untreated mice. All mice are age matched and the injected mice were examined at 2 months post-injection. N = 4
per treatment group, p-values from unpaired t-test.
Levels of proteins involved in autophagy and
lysosomal activity are changed in the striatum
of mice treated with AAV hSyn1 TFEB-HA
Since TFEB is known to activate autophagy path-
ways and lysosomal activity, we performed Western
blot assays in crude homogenates (CH) and subcel-
lular fractions (P1, S2 and P2) of striatum to assess
the effects of TFEB-HA expression on levels and
distribution of selected proteins including LAMP-
2A, LC3II, procathepsin D, HSC70 and Rab7. The
results were compared to striatum with no injec-
tion. At two months after treatment with AAV
hSyn1 TFEB-HA, the striatum of HDQ175/Q7 mice
had significant increases in levels of LAMP-2A (in
CH, P1, and P2 fractions), LC3II (in CH), and
procathepsin D 46kD (in CH and P1 fractions) com-
pared to striatum of non-injected mice (Fig. 3A,
B). By contrast, there were significant reductions
in the levels of HSC70 and Rab7 in S2 fractions
of the TFEB-HA treated HDQ175/Q7 striatum com-
pared to the untreated striatum (Fig. 3B). These data
suggest that TFEB-HA expression in the striatum of
HDQ175/Q7 mice promotes autophagy and lysosomal
activity.
Analysis of mutant HTT levels in striatum
of HDQ175/Q7 mice injected with AAV hSyn1
TFEB-HA
Since mHTT may be processed through autophagy
[9, 12, 35], we looked at the levels of mHTT after
TFEB-HA expression. MHTT levels were examined
by Western blot with N-terminal directed HTT anti-
bodies (EPR5526 HTT 1–100 and Ab1 HTT 1–17
antibodies). In the striatum of HDQ175/Q7 mice, full
length mHTT levels were reduced by 21–35%, in
CH, P1 and P2 fractions when detected with anti-
body EPR5526 (Fig. 3C, D). Although a similar
trend for reduction in mHTT levels was observed
using antibody Ab1 (–21% in P1, –31% in P2), the
changes were not significant by statistical analysis
(results not shown). There was no reduction in lev-
els of WT HTT in the TFEB-HA injected HDQ175/Q7
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Fig. 4. Western blot analysis of DARPP32, GFAP, PDE10A in striatal crude homogenates of mice injected with either AAV hSyn1 TFEB-HA
or non-injected. A) Western blots for DARPP32, GFAP and PDE10A, GAPDH was used as a loading control. B) Bar graphs show results
of densitometry for Western blots in A. All mice are age matched and the injected mice were examined at 2 months post-injection. Each
column represents sample from a different mouse, N = 4 mice per treatment group, p-values from unpaired t-test.
compared to untreated mice when detected with anti-
body EPR5526 (Fig. 3C, D) or with antibody Ab1
(results not shown). These results suggest that TFEB-
HA expression may lower levels of mHTT in vivo.
However, the findings must be interpreted cautiously
due to the small reductions in mHTT levels and
the lack of confirmation with a second anti-HTT
antibody.
Effects of AAV hSyn1 TFEB-HA expression on
protein levels of DARPP32, PDE10A and GFAP
Since the staining for DARPP32 and GFAP was
altered in striatal areas of TFEB-HA distribution,
we performed Western blot analysis to determine
the levels of these proteins and also the striatal
enriched protein PDE10A. Compared to non-injected
mice, AAV hSyn1 TFEB-HA injected mice sur-
viving two months had lower levels of DARPP32
(–14%, p = 0.093) that were not statistically signif-
icant, a significant decline in levels of PDE10A
(–55%, p = 0.002) and a significant increase in the
levels of GFAP (+154%, p = 3.3E-05) (Fig. 4A, B).
We also compared the levels of DARPP32, PDE10A
and GFAP in AAV hSyn1 TFEB-HA injected and
AAV hSyn1 GFP injected mice at one month post-
injection. Compared to the striatum of HD mice
injected with AAV hSyn1 GFP, the striatum of HD
mice injected with AAV hSyn1 TFEB-HA had a sig-
nificant reduction in DARPP32 (–39%, p = 0.0136)
and PDE10A (–80%, p = 5E-04) and significant
increase in GFAP (141%, p = 7E-04) (Supplemen-
tary Figure 2A, B). The reduction in DARPP32 (at
one month post-injection) and the decline in PDE10A
and increase in GFAP (at one and two months post-
injection) suggested that TFEB-HA expression in
striatum of HDQ175/Q7 mice caused some neuronal
stress.
Analysis of apoptosis and ER stress
We analyzed striatal lysates from AAV hSyn1
TFEB-HA injected and non-injected mice for
markers of apoptosis (caspase 3 cleavage, PARP-
1 cleavage) and endoplasmic reticulum stress
(GRP78/BiP). We did not detect cleavage of caspase
3 or PARP-1 (data not shown), which would indicate
ongoing apoptosis. However, levels of procaspase 3
(35 kDa) were significantly increased in HDQ175/Q7
mice injected with AAV hSyn1 TFEB-HA compared
to non-injected mice (Fig. 5A, B, +23%, p = 0.019).
In non-injected HDQ175/Q7 mice GRP78/BiP levels
were significantly increased compared to age-
matched WT mice (Fig. 5A, B, +24%, p = 0.020) and
elevated by further 24% (p = 0.051) in TFEB-HA
injected HDQ175/Q7 mice. These results suggested
that ER stress response is activated in HD mice and
TFEB-HA expression in the striatum enhances this
activation.
DISCUSSION
TFEB regulates lysosomal biogenesis and
autophagy [29], and in cell models of neurodegen-
erative disease its expression has been shown to
reduce disease proteins that cause neurodegeneration
[26, 36]. TFEB-HA expression in the striatum of
HDQ175/Q7 mice with the hSyn1 promoter generated
expression in neurons and both cytoplasmic and
nuclear localization. The latter is important since
function of TFEB as a transcription factor requires
its nuclear localization which is partly controlled by
phosphorylation state [37]. TFEB-HA expression in
the striatum of HDQ175/Q7 mice increased a num-
ber of regulatory proteins involved in autophagy.
The increase in levels of LAMP-2A, LC3II and
procathepsin D in crude homogenates (CH) and
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Fig. 5. Western blot analysis of apoptosis and ER stress markers in striatal crude homogenates of HDQ175/Q7 mice injected with AAV hSyn1
TFEB-HA or non-injected HDQ175/Q7 and WT mice. A) Western blots for GRP78/BiP and procaspase 3 in HDQ175/Q7 mice injected with
AAV hSyn1 TFEB-HA and non-injected HDQ175/Q7 and WT mice. GAPDH was used as a loading control. B) Bar graphs show results of
densitometry for Western blots in A. All mice are age matched and the injected mice were examined at 2 months post injection. Each column
represents sample from a different mouse, N = 4 mice per treatment group, p-values from unpaired t-test.
membrane fractions (P1 or P2) is consistent with the
function of these proteins at membranes and with a
TFEB induced increase in the number of autophago-
somes (LC3II) and lysosomes (LAMP-2A and
procathepsin D). Unexpectedly, the levels of Rab7
and HSC70 in the soluble fraction were reduced
rather than increased by TFEB-HA expression in
HDQ175/Q7. Rab7 is important for trafficking cargo
to lysosomes, and HSC70 is important for clearance
by chaperone mediated autophagy. The reduced
levels of these proteins arising possibly from a TFEB
induced increase in autophagic flux suggest that
some imbalances in the autophagy pathways may be
triggered by TFEB-HA expression in brain.
It is interesting that TFEB-HA expression reduced
the levels of mHTT (by 21–35% in membrane frac-
tions), but not the levels of WT HTT. Aggregation
prone proteins such as mHTT are often targeted
for degradation by autophagy [35, 38, 39], and
thus TFEB expression may preferentially enhance
autophagy dependent degradation of mHTT com-
pared to WT HTT. Tsunemi et al. showed that
overexpression of PGC-1 in HD mouse striatum
reduced the number of cells with typical mHTT inclu-
sions through a TFEB mediated mechanism [26].
TFEB-HA expression driven by the hSyn1 pro-
moter in HDQ175/Q7 mice caused increased levels of
GFAP, a sign of reactive astrocytosis. The increase
in GFAP is unlikely due to direct effects of exoge-
nous TFEB in astrocytes since the activity of the
hSyn1 promoter is restricted to neurons [40]. Reac-
tive astrogliosis is a common response to insults
that disrupt neuronal homeostasis [41]. The TFEB-
HA induced changes in medium spiny neurons
represented by reduced levels of DARPP32 and
PDE10A may have triggered a response in astrocytes.
Astrocytes in symptomatic HDQ175/Q7 mice are not
reactive [42] as they are in human HD [43] but do
have a potassium channel dysfunction [42].
The marked decline in the levels of PDE10A that
occurred in HD striatum after TFEB-HA expres-
sion is intriguing. Phosphodiesterase PDE10A is
highly expressed in striatal neurons [28] and regu-
lates dopamine receptor D1 and D2 signaling through
reduction of cAMP [44]. Recently it was shown that
changes in lysosomal pH present in some neurode-
generative diseases (familial AD with presenilin1
mutation) can be partly restored by cAMP treatment
[45]. One possibility is that reductions in PDE10A
seen after TFEB-HA expression increase the levels
of cAMP, which in turn increases lysosomal func-
tion. Treatment with PDE10A inhibitor TP-10 was
reported to be protective in the R6/2 HD mouse model
[46]. However, in our study the reduction in PDE10A
may have also contributed to the freezing behav-
ior we observed in the HDQ175/Q7 mice. PDE10A
null mice show reduced spontaneous locomotor
activity [47].
We observed elevated levels of the ER chaperone
protein GRP78/BiP in non-injected HD mice as com-
pared to non-injected WT mice. There is evidence
that GRP78/BiP is increased in the presence of the
HD mutation and is part of the protective response to
ER stress. Reijonen et al. showed that cells express-
ing N-terminal mHTT had increased GRP78/BiP
and treatment with the ER stress inhibitor salu-
brinal prevented caspase-12 cleavage and protected
cells from apoptosis, increased viability, and reduced
mHTT fragment aggregation [48]. In Neuro-2 cells,
GRP78/BiP overexpression prevented HTT150Q
mediated Caspase-3 activation and increased cell
survival, while siRNA mediated GRP78/BiP silenc-
ing increased HTT150Q induced cell death and
Caspase-3 activation [49]. In our TFEB-HA injected
258 P. Vodicka et al. / Exogenous TFEB Expression in HDQ175/Q7 Mice
HDQ175/Q7 mice, a trend for further increase in
GRP78/BiP compared to non-injected HDQ175/Q7
occurred along with the rise in procaspase-3 levels.
This GRP78/BiP elevation and absence of caspase 3
cleavage may be part of a protective response to ER
stress.
In summary our findings show that in vivo expres-
sion of TFEB in the HD striatum is effective
in elevating proteins that signal the activation of
autophagy. Autophagic degradation is likely to have
played a role in reducing levels of mHTT protein.
The expression of TFEB-HA in HD striatum also
caused changes in PDE10A and DARPP32 and a
protective response to ER stress. Our results sug-
gest that over-expression of TFEB may be harmful in
vivo. Study of the effects of TFEB expression in HD
mice beyond 2 months will be needed to determine
if TFEB is useful for sustained autophagy activa-
tion and lowering of mHTT levels and in delaying
motor deficits caused by the HD mutation. TFEB
expression from a weaker promoter than hSyn1 may
reduce adverse effects such as ER stress and reactive
gliosis while still activating autophagy and reducing
mHTT levels.
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